{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-072768","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2026-11-10T21:23:34+00:00","discovered_at":"2026-11-10T21:24:00.253316+00:00","generated_at":"2026-11-10T21:24:06.848603+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Context Therapeutics Q3 net loss $7.6M; CTIM-76 shows 22% ORR in PROC at weekly doses","bullets":["Q3 2026 net loss $7.6M vs $9.7M in Q3 2025; R&D $5.7M vs $8.7M, G&A $2.2M vs $1.9M.","Cash and equivalents $34.4M at Sept 30, 2026, down from $66.0M at Dec 31, 2025; runway expected into early Q4 2027.","CTIM-76 in 9 efficacy-evaluable PROC patients at 140–280 µg weekly: 22% confirmed ORR, 56% DCR, median PFS 5.6 months.","Safety: CRS in 5 of 27 patients (18.5%), all Grade 1/2; Grade ≥3 TEAEs in 81.5%, with dose-related Grade ≥3 liver enzyme elevations.","DLT period at 280 µg every three weeks complete; escalation to 420 µg Q3W begun; Phase 1b initiation expected Q1 2027, initial Q3W efficacy data Q2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-072768","json":"https://secwatch.observer/filing/0001628280-26-072768.json","markdown":"https://secwatch.observer/filing/0001628280-26-072768.md","text":"https://secwatch.observer/filing/0001628280-26-072768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026072768/0001628280-26-072768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026072768/cntx-20261110.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:24:06.848603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}